Patents by Inventor Francois Rouzet

Francois Rouzet has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11154625
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: October 26, 2021
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS 13
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Publication number: 20160206762
    Abstract: The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-PA) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.
    Type: Application
    Filed: January 20, 2016
    Publication date: July 21, 2016
    Applicants: Institut National de la Sante et de la Recherche Medicale, Pharmaleads, Assistance Publique Hopitaux de Paris, Universite Paris Diderot - Paris 7
    Inventors: Jean-Baptiste Michel, Francois Rouzet, Dominique Leguludec, Herve Poras, Marie-Claude Fournie-Zaluski, Bernard Roques
  • Patent number: 9272054
    Abstract: The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-PA) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: March 1, 2016
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Pharmaleads, Assistance Publique Hopitaux de Paris, Universite Paris Diderot-Paris 7
    Inventors: Jean-Baptiste Michel, François Rouzet, Dominique Leguludec, Hervé Poras, Marie-Claude Fournie-Zaluski, Bernard Rogues
  • Publication number: 20140134102
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: January 17, 2014
    Publication date: May 15, 2014
    Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Publication number: 20130243691
    Abstract: The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-PA) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity.
    Type: Application
    Filed: December 5, 2011
    Publication date: September 19, 2013
    Applicant: PHARMALEADS
    Inventors: Jean-Baptiste Michel, François Rouzet, Dominique Leguludec, Hervé Poras, Marie-Claude Fournie-Zaluski, Bernard Roques
  • Publication number: 20120183475
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: January 9, 2012
    Publication date: July 19, 2012
    Applicant: INSERM (Institut National de la sante et de la Recherche Medicale)
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
  • Publication number: 20120093725
    Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.
    Type: Application
    Filed: April 10, 2009
    Publication date: April 19, 2012
    Applicant: Inserm (Institut National de la Sante et de la Recherche Medicale
    Inventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans